Scaling Synthetic Biology: Why Anxiety Peaks at $5M ARR
Synthetic biology founders in India face a discrete anxiety inflection around $5M ARR. Regulatory complexity, supply chain fragility, and IP uncertainty collide simultaneously. Recognizing these patterns early prevents costly pivots.
Get 1 unfair insight every week from India's startup ecosystem.
Read by serious founders and investors. No fluff.
Continue reading with Blog Pass
This piece is part of the Aletheia archive. This week’s drops are free — unlock every sector thesis, deal-flow breakdown and disclosure note with a Blog Pass.
Amit Tyagi
Founder, AletheiaAI & GP, Fitoor Capital
Veteran of India's startup ecosystem. Writing about fundraising, investor psychology, and what it takes to build fundable startups in India.
Run a fundability check
India's only MRE-backed platform for founders and investors. Analyse your deck, find investors, and validate your raise strategy.
Don’t miss the next one
One insight every week. No fluff.
One contrarian insight. Every week. No generic startup advice.
Join founders and investors building with better information.